[Systemic adjuvant chemotherapy of bladder carcinoma with 5 fluorouracil and cyclophosphamide].
Patients with bladder cancer in pT2 and pT3 infiltrating stages have a 5 year survival rate less than 50% after primary surgical and/or radiant therapy. Aim of the present study was to evaluate if adjuvant chemotherapy could improve survival in these subjects. For this purpose, 16 patients underwent treatment with 5-Fluorouracil and cyclophosphamide (min. three, max six courses). The obtained results have shown a 5 year actuarial survival rate of about 48%. Our experience has not shown therefore any improvement compared with primary treatment alone.
Sbalzarini
G
G
Divisione Medica I, USSL n. 56, Ospedale Maggiore, Lodi, Milano.
Giuberti
A C
AC
Pandolfi
C
C
Del Boca
C
C
Labadini
A
A
Bolognini
G
G
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery
D003520:Cyclophosphamide; D005472:Fluorouracil
Chemioterapia adiuvante sistemica del carcinoma vescicale con 5 fluorouracile e ciclofosfamide.